Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

Agenus Inc.
Posted on: 04 Sep 18
Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

PR Newswire

LEXINGTON, Mass., Sept. 4, 2018

LEXINGTON, Mass., Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus and Robert Stein, MD, PhD, Senior R&D Advisor at Agenus, will make a presentations and host one-on-one meetings with investors at the 2018 Annual B. Riley FBR Healthcare Conference, at NY Marriott East Side in New York City.

Details of the presentation are provided below:

  • Presenter: Jennifer S. Buell, PhD
    Tue, Sep 4 at 11:20-12:20 PM in Stuyvesant Room
    Panel: Rational Immuno-oncology Combinations Are Not Necessarily Predictive
  • Presenter: Robert B. Stein, MD, PhD
    Tue, Sep 4 at 1:55-2:55 PM in Stuyvesant Room
    Panel: Vaccine & Antibiotics Can't Be Developed For Some Intractable Infectious Diseases

About Agenus Inc.

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' upcoming presentation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

View original content with multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-annual-b-riley-fbr-healthcare-conference-in-new-york-city-300706221.html

SOURCE Agenus Inc.

PR Newswire
www.prnewswire.com

Last updated on: 04/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.